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Osteoporosis commonly affects most postmenopausal women, placing them at a
significant risk for fractures. Alendronate has widely been used as a first line drug
in the treatment of osteoporosis in postmenopausal women, because current
evidence, based strictly on the principles of evidence-based medicine (EBM),
suggests both the anti-fracture efficacy and safety of alendronate in postme-
nopausal women with osteoporosis.
1-4 According to the results of randomized
controlled trials (RCTs) and meta-analyses of RCTs in postmenopausal women
with osteoporosis, alendronate effectively prevents vertebral, nonvertebral, and
hip fractures across a spectrum of ages.
1-3,5-9
Since increasing longevity in men has increased the public health burden of
osteoporotic fractures in men, great attention has been paid also to male osteo-
porosis. Alendronate has been approved by the United States Food and Drug
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turnover have already been established in postmenopausal women with osteoporosis. An open-labeled prospective
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alfacalcidol (1 µg daily) groups. The BMD of the total hip, urinary level of cross-linked N-terminal telopeptides of
type I collagen (NTX), and serum levels of bone-specific alkaline phosphatase (BSAP) were measured during the
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INTRODUCTIONAdministration (US FDA) for the treatment of male osteo-
porosis. However, the efficacy of alendronate for male
osteoporosis has been less established, because there have
only been a few strictly conducted RCTs on the efficacy of
alendronate in men with osteoporosis.
10
It is well known that hip fractures are an important cause
of mortality and morbidity among elderly patients with
osteoporosis.
11-13 It has been established in postmenopausal
women with osteoporosis that anti-resorptive therapies that
produce larger decreases in bone turnover markers with
larger increases in bone mineral density (BMD) are
associated with greater reductions in the risk for non-
vertebral fractures, especially at sites primarily composed
of cortical bone.
14 In particular, postmenopausal women
who are treated with alendronate and show the greatest
percent reduction in bone-specific alkaline phosphatase
(BSAP) have the lowest risk for hip fractures, while those
with the smallest reduction in BSAP have the highest risk
for hip fractures.
15 Alendronate-treated postmenopausal
women with at least 30% reduction in BSAP have a 74%
lower risk for hip fractures than those with less than 30%.
15
Although the efficacy of alendronate against vertebral
fractures seems to have been established in male osteo-
porosis,
16 the efficacy of alendronate in men in relation to
reduction in the risk of hip fractures remains to be
established, probably because of the insufficient sample
sizes for a RCT. Thus, the improvement of surrogate
markers such as hip BMD and bone turnover markers is
thought to be important in the prevention of hip fractures
in elderly men with an increased risk for fractures.
Several studies have reported the comparative effects of
alendronate or risedronate and alfacalcidol on BMD and
bone turnover in Caucasian men with osteoporosis.
17-20 To
our knowledge, however, there are no data to show the
effects of alendronate on hip BMD and bone turnover in
Japanese men with osteoporosis. The purpose of this open-
labeled prospective study was to compare the effects of
alendronate and alfacalcidol (active control) on hip BMD
and bone turnover in Japanese men having osteoporosis or
osteopenia with clinical risk factors for fractures. The
primary end point was hip BMD, and the secondary end
point was bone turnover markers.
Subjects
One hundred twelve men having osteoporosis or osteo-
penia with clinical risk factors for fractures (mean age:
71.4 years) were recruited at Keiyu Orthopaedic Hospital
(Gunma, Japan) during the 27 months between January
2005 and March 2007. According to the Japanese diagnostic
criteria,
21,22 patients with BMD < 70% of the young adult
mean (YAM) or 70 - 80% of the YAM along with a history
of osteoporotic fractures are diagnosed as having osteopo-
rosis. Patients with BMD of 70 - 80% of the YAM without
any history of osteoporotic fractures are diagnosed as
having osteopenia. Patients having osteoporosis or osteo-
penia with clinical risk factors for fractures such as current
smoking, alcohol abuse (≥ 2 units a day), and a history of
steroid use are treated with drugs.
23 The patients in the
present trial were randomly divided into two groups of 56
patients each: the alendronate (5 mg daily) group (35
patients with osteoporosis and 21 patients with osteopenia
+ clinical risk factors for fractures) and the alfacalcidol (1
µg daily) group (31 patients with osteoporosis and 25
patients with osteopenia + clinical risk factors for fractures).
The doses indicated in the parentheses are the doses used
mainly in elderly Japanese women with osteoporosis, and
have been recognized as safe and effective.
24-26 In particular,
the dose of alendronate in Japan, which was approved by
the Ministry of Health, Labor and Welfare, is half of that
used in other countries according to the results of the phase
II study showing that alendronate at 5 mg daily adequately
suppressed bone turnover and increased lumbar BMD in
postmenopausal women with osteoporosis.
24 The duration
of treatment was 12 months.
Preliminary screening included medical history, physical
examination, plain X-rays of the thoracic and lumbar
spine, hip BMD measurement, and blood and urinary
biochemical tests. Subjects with a history of reflux esopha-
gitis, gastric or duodenal ulcers, gastrectomy, or renal
stone were excluded. Hip BMD was measured, and the
assessment of vertebral fractures on plain X-ray films was
performed as described below. The serum levels of calcium,
phosphorus, alkaline phosphatase (ALP), and intact
parathyroid hormone (PTH) were measured using standard
laboratory techniques. The serum level of BSAP was
measured with an enzyme immunoassay (EIA). The
urinary level of cross-linked N-terminal telopeptides of type
I collagen (NTX) was measured with an enzyme-linked
immunosorbent assay (ELISA). None of the subjects had
ever taken medication to treat osteoporosis prior to the
present study. All the subjects were instructed to consume
about 800 mg of dietary calcium daily (the minimum
requirement of calcium intake in elderly Japanese) during
the study period. Informed consent was obtained from
each participant prior to his participation in the study.
Table 1 illustrates the baseline characteristics of the
study subjects. There were no significant differences in
any of the baseline characteristics between the two groups
(as determined by the unpaired t-test and Fisher’s exact
test). The past histories of the subjects that could affect
bone metabolism were steroid use [asthma (n = 9), hearing
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MATERIALS AND METHODSloss (n = 5), and rheumatoid arthritis (n = 1)], diabetes
mellitus (n = 7), hepatitis (n = 1), and cerebrovascular
disease with no apparent hemiplegia (n = 3). The urinary
level of NTX (normal range: 9.3 - 54.3 nM BCE/mM Cr),
serum levels of BSAP (normal range: 7.9 - 29.0 U/L) and
intact PTH (normal range: 10 - 66 pg/mL) tended to be
higher within or above the normal ranges.
27 The serum level
of ALP was within the normal range (100 - 340 IU/L). After
the start of the treatment, the urinary level of NTX was
measured at 3 months, the hip BMD and serum levels of
calcium, phosphorus, BSAP, and intact PTH at every 6
months, and plain X-rays of the thoracic and lumbar spine
at the end of 12 months’ treatment. We compared changes
in hip BMD, urinary NTX, and serum calcium, phos-
phorus, BSAP, and intact PTH levels between the two
groups. This protocol was approved by the Ethics Com-
mittee of Keiyu Orthopaedic Hospital.
Measurement of hip BMD
The BMD of the left total hip in the anteroposterior view
was measured by dual-energy X-ray absorptiometry
(DXA) using a Hologic QDR 1500W apparatus (Bedford,
MA, USA). The coefficient of variation (100×standard
deviation/mean) of the three measurements with reposi-
tioning within 24 hours each time was less than 1.2% in
three persons.
Assessment of vertebral fractures
Plain lateral X-ray films of the thoracic and lumbar spine
were obtained to detect evidence of vertebral fractures. Ac-
cording to the Japanese criteria, a vertebral fracture is
defined according to the vertebral height on lateral X-ray
films.
21,22 In brief, the vertebral height is measured at the
anterior (A), central (C), and posterior (P) parts of the
vertebral body, and the presence of a vertebral fracture is
confirmed when 1) a reduction in the vertebral height of
more than 20% (A, C, and P) as compared to the height of
the adjacent vertebrae is observed, 2) the C/A or C/P is less
than 0.8, or 3) the A/P is less than 0.75. The assessment of
vertebral fractures was performed at the T4-L4 level. This
assessment was non-blinded and performed by one
investigator.
Statistical analysis
Data were expressed as mean ± standard deviation (SD) in
the tables and as mean ± standard error (SE) in the figures.
Data were compared between the two groups by unpaired
t-test. The number of patients with a history of fracture and
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Table 1.Characteristics of Study Subjects
Alendronate Alfacalcidol Normal
(n = 56) (n = 56) range
Age (yrs) 70.8 ± 10.5 72.1 ± 10.5
Height (m) 1.62 ± 0.07 1.60 ± 0.09
Body weight (kg) 55.7 ± 9.4 53.6 ± 8.0
Body mass index (kg/m
2) 21.1 ± 3.1 21.0 ± 2.4
Total hip BMD (g/cm
2) 0.690 ± 0.068 0.714 ± 0.079
%YAM of the BMD  66.3 ± 6.5 68.5 ± 7.6
Serum calcium (mg/dL) 9.2 ± 0.5 9.0 ± 0.4 8.5 - 10.2
Serum phosphorus (mg/dL) 3.0 ± 0.4 3.0 ± 0.6 2.8 - 4.6
Serum ALP (IU/L) 293 ± 91 269 ± 85 100 - 320
Serum BSAP (U/L) 29.8 ± 11.8 26.8 ± 10.7 13.0 - 33.9
Serum intact PTH (pg/mL) 40.5 ± 17.7 38.8 ± 14.4 10 - 65
Urinary NTX (nM BCE/mM Cr) 55.8 ± 24.8 50.6 ± 22.2 9.3 - 54.3
Number (%) of current smoker 15 (26.8) 18 (32.1)
Number (%) of patients with a history of 
8 (14.3) 7 (12.5)
steroid use
Number (%) of patients with a history of 
26 (46.4) 29 (51.8)
fracture ≥50 years of age
Number (%) of patients with alcohol abuse 
12 (21.4) 16 (28.6)
(≥2 units a day)
BMD, bone mineral density, YAM, young adult mean; ALP, alkaline phosphatase; BSAP, bone-specific ALP; PTH, parathyroid 
hormone; NTX, cross linked N-terminal telopeptides of type I collagen; BCE, bone collagen equivalent. 
Data are expressed as the mean ± SD. There were no significant differences in any characteristics between the two groups (by the
unpaired t-test and Fisher’s exact test).clinical risk factors for fractures were compared in the two
groups by Fisher’s exact test. The significance of longitu-
dinal changes in the parameters was determined with the
one-way analysis of variance (ANOVA) with repeated
measurements. The longitudinal changes in the parameters
were compared between the two groups with the two-way
ANOVA with repeated measurements. All statistical
analyses were performed using the Stat View-J5.0 pro-
gram on a Windows computer. A significance level of p <
0.05 was used for all the comparisons.
Adverse events
Eleven patients (19.6%) in the alendronate group and 14
patients (25.0%) in the alfacalcidol group discontinued
treatment during the 12-month-period. The main reasons
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Table 2.Results of ANOVA with Repeated Measurements
One-way ANOVA Two-way ANOVA
Alendronate Alfacalcidol Alendronate  vs. Alfacalcidol
Total hip BMD p < 0.05 NS p < 0.01
Serum
Calcium NS p < 0.0001 p < 0.001
Phosphorus NS NS NS
BSAP p < 0.0001 NS p < 0.0001
Intact PTH NS NS NS
Urinary NTX p < 0.0001 NS p < 0.0001
BMD, bone mineral density; BSAP, bone-specific alkaline phosphatase; PTH, parathyroid hormone; NTX, cross linked N-terminal 
telopeptides of type I collagen; NS, not significant. 
The one-way analysis of variance (ANOVA) with repeated measurements was used to examine the longitudinal changes in BMD and
biochemical markers in the alendronate and alfacalcidol groups. The two-way ANOVA with repeated measurements was used to
compare the longitudinal changes in BMD and biochemical markers between the two groups.
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Fig. 1. Percent changes in serum calcium, phosphorus, BSAP and PTH. Data are expressed as the mean ±SE. The serum level of BSAP significantly decreased,
but the serum levels of calcium, phosphorus, and intact PTH did not significantly change in the alendronate group (one-way ANOVA with repeated measurements,
Table 2). The serum level of calcium significantly increased, but the serum levels of phosphorus, BSAP, and intact PTH did not significantly change in the
alfacalcidol group (one-way ANOVA with repeated measurements, Table 2). There were significant differences in changes in the serum levels of calcium and
BSAP between the two groups (two-way ANOVA with repeated measurements, Table 2). n = 45 in the alendronate group and n =  42 in the alfacalcidol group.
BSAP, bone-specific alkaline phosphatase; PTH, parathyroid hormone. 
RESULTSfor the dropouts from the study were epigastric pain (n = 8)
and difficulty with compliance (n = 3) in the alendronate
group, and epigastric pain (n = 3), difficulty with
compliance (n = 10), and surgery for osteoarthritis of the
knee (n = 1) in the alfacalcidol group. No serious adverse
events necessitating hospitalization were observed in either
group. Thus, the trial was successfully completed in 45
(80.4%) patients in the alendronate group and 42 (75.0%)
patients in the alfacalcidol group, and the data from a total
of 87 patients (77.7%) were included in the analyses.
There were no significant differences in any of the
baseline characteristics between 45 patients in the
alendronate group and 42 patients in the alfacalcidol group
who completed the 12-month trial.
Changes in serum and urinary biochemical markers
and hip BMD
With regard to the percent changes (mean ± SE) in the
urinary level of NTX at 3 months, the urinary level of
NTX was significantly decreased (-46.4 ± 2.9%) in the
alendronate group, but did not change significantly (+13.2
± 12.5%) in the alfacalcidol group (one-way ANOVA
with repeated measurements, Table 2). There was a
significant difference in changes in the urinary level of
NTX between the two groups (two-way ANOVA with
repeated measurements, Table 2).
Fig. 1 shows the longitudinal changes in the serum levels
of calcium, phosphorus, BSAP, and intact PTH. The serum
level of BSAP was significantly decreased (-27.5% at 6
months and -34.1% at 12 months), but the serum levels of
calcium (-1.1% at both 6 and 12 months), phosphorus (-3.3%
at 6 months and -4.2% at 12 months), and intact PTH
(+7.1% at 6 months and +7.6% at 12 months) did not
significantly change in the alendronate group (one-way
ANOVA with repeated measurements, Table 2). On the
other hand, the serum level of calcium increased signifi-
cantly (+1.5% at 6 months and +2.2% at 12 months), but the
serum levels of phosphorus (+1.3% at 6 months and +0.5%
at 12 months), BSAP (+1.4% at 6 months and +1.8% at 12
months), and intact PTH (-6.3% at 6 months and -7.5% at
12 months) did not significantly change in the alfacalcidol
group (one-way ANOVA with repeated measurements,
Table 2). There were significant differences in changes in the
serum calcium and BSAP levels between the two groups
(two-way ANOVA with repeated measurements, Table 2).
Fig. 2 shows the longitudinal changes in total hip BMD.
The BMD increased significantly (+1.5% at 6 months and
+2.3% at 12 months) in the alendronate group, but did not
significantly change (-1.8% at 6 months and -1.9% at 12
months) in the alfacalcidol group (one-way ANOVA with
repeated measurements, Table 2). There was a significant
difference in changes of BMD between the two groups
(two-way ANOVA with repeated measurements, Table 2).
A prospective head-to-head trial was conducted to
compare the effects of alendronate and alfacalcidol (active
control) on hip BMD and bone turnover in Japanese men
with osteoporosis or osteopenia with clinical risk factors for
fractures. The focus of the discussion was whether alendro-
nate would successfully increase hip BMD following
reductions in bone turnover markers, including serum
BSAP and urinary NTX, compared with alfacalcidol
(active control). Because of the small sample size of men
with an increased risk for fractures, the assessment of
surrogate markers such as hip BMD and bone turnover
markers may be important from the point of view of the
prevention of hip fractures in men having osteoporosis or
osteopenia with clinical risk factors for fractures.
The higher risk of osteoporotic fractures in men is consi-
dered to accrue from a lower peak volumetric BMD and
greater bone loss with aging, particularly in those subjects
with risk factors, hypogonadism, or underlying illness.
28 It
is likely that bone formation, as reflected by bone forma-
tion markers, decreases with aging and in the presence of
fractures in men.
28 On the other hand, bone resorption, as
reflected by bone resorption markers, may increase in late
life, probably reflecting increased bone turnover associated
with secondary hyperparathyroidism.
28 However, it still
remains controversial as to whether male osteoporosis is
caused mainly by increased bone resorption, even though
increased or decreased bone turnover has been reported in
men with vertebral fractures.
29,30
In the present study, twenty-six patients (23.2%) had
illnesses that could affect bone metabolism, and the
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Fig. 2. Percent changes in total hip BMD. Data are expressed as the mean ±
SE. The BMD significantly increased, but did not significantly change in the
alfacalcidol group (one-way ANOVA with repeated measurements, Table 2).
There was a significant difference in changes in the BMD between the two
groups (two-way ANOVA with repeated measurements, Table 2). n = 45 in the
alendronate group and n = 2 in the alfacalcidol group. BMD, bone mineral
density. 
DISCUSSIONurinary level of NTX and serum levels of BSAP and intact
PTH at the baseline tended to be higher within or above
the normal ranges. Thus, anti-resorptive drugs might have
been expected to be efficacious in our subjects.
Alfacalcidol is known to suppress bone resorption and
maintain or even increase bone formation, suggesting that
alfacalcidol supercouples bone formation and resorption.
31
Alfacalcidol suppresses the synthesis and release of PTH
and increases the intestinal absorption and reabsorption of
calcium in the distal renal tubules.
32 In rats, alfacalcidol has
been shown to improve the microarchitecture and strength
of bone.
31,33 Vitamin D supplementation appears to reduce
the risk for falls among ambulatory or institutionalized
older individuals with stable health by more than 20%.
34 In
the present study, alfacalcidol, an active control drug, sus-
tained total hip BMD (-1.9% at 12 months) as well as the
urinary level of NTX (+13.2% at 3 months) and serum
level of BSAP (+1.8% at 12 months) in men with an
increased risk for fractures, although we did not assess the
incidence of falls. Because of the similar baseline bone
turnover status in two different categories such as
osteoporosis and osteopenia + clinical risk factors for
fractures, the BMD change during 12-month treatment was
similar in the two categories (data not shown). Higher bone
turnover tended to cause a reduction in total hip BMD, but
the BMD loss was not statistically significant, probably
due to the small sample size and short-duration of the
study. These effects of alfacalcidol seem to be less
pronounced compared with those of previous studies in
Caucasian men with osteoporosis.
17,18 One possibility is
that alfacalcidol might be less effective in our subjects,
probably because of the smaller number of patients with
vitamin D insufficiency or deficiency as indicated by the
serum level of ALP.
35
On the other hand, alendronate increased total hip BMD
(+2.3% at 12 months) following reductions in the urinary
level of NTX (-46.4% at 3 months) and serum level of
BSAP (-34.1% at 12 months). Because of the similar base-
line bone turnover status in two different categories such
as osteoporosis and osteopenia + clinical risk factors for
fractures, the BMD change during 12-month treatment
was similar in the two categories (data not shown). These
changes were significantly different between the alendro-
nate and alfacalcidol (active control) groups, suggesting
the efficacy of alendronate for hip BMD and bone turnover
in men having osteoporosis or osteopenia with clinical risk
factors for fractures. In other words, alendronate improved
surrogate markers in relation to hip fractures in men with
an increased risk for fractures. The effects of alendronate
on hip BMD and bone turnover markers seemed to be
compatible with those in Caucasian men with osteopo-
rosis.
10,16,18,19 Because each 1 standard deviation reduction in
a 1-year change in BSAP is associated with 39% fewer hip
fractures in alendronate-treated postmenopausal women,
15
a reduction in the serum level of BSAP (-34.1% at 12
months) could possibly contribute to a reduction in the
incidence of hip fractures in our subjects.
A randomized, double-placebo, double-blind clinical
trial conducted over a duration of 18 months’ among
patients with a rheumatic disease who were starting
glucocorticois showed that total hip BMD was increased
by 0.8% in the alendronate group and decreased by 2.2%
in the alfacalcidol group.
36 Alendronate suppressed bone
resorption and increased serum PTH levels, while
alfacalcidol slightly increased bone formation.
36 These
results suggested that alendronate was more effective in
the prevention of glucocorticoid-induced bone loss than
alfacalcidol, in agreement with our results.
Eleven patients (19.6%) in the alendronate group
dropped out from the study, and the main reason for the
dropouts was gastric problems. Adverse upper gastroin-
testinal (GI) symptoms are considered to be the most
significant adverse effects of alendronate in clinical
practice, even though RCTs show no statistically
significant difference in the incidence of adverse upper GI
events between men with osteoporosis treated with
alendronate and a placebo.
10 Increased sensitivity for the
detection of upper GI symptoms in the study subjects might
have been more likely than the existence of a causal
relationship between upper GI symptoms and alendronate.
On the other hand, 14 patients (25.0%) in the alfacal-
cidol group dropped out from the study, and the main
reason for the dropouts was difficulty with compliance.
The worrisome adverse effect associated with alfacalcidol
may be hypercalcemia, because this drug stimulates
intestinal calcium absorption. In the present study, the
serum level of calcium trended to increase (+1.5% at 6
months and +2.2% at 12 months) from the baseline (the
mean value: 9.0 mg/dL). However, no patients experienced
renal dysfunction, including acute renal failure, due to
hypercalcemia. No case of hypercalcemia was documented
in men treated with alfacalcidol (1 µg daily) in a previous
study.
18 Probably because of insignificant changes in BMD
and bone turnover markers during the treatment, adherence
to alfacalcidol might have been worse than that to
alendronate, resulting in a larger number of patients who
discontinued the trial due to noncompliance.
There were some notable limitations of this study.
Firstly, the study was not a double-blind trial, but an open-
labeled study. Therefore, some of the results might have
been biased. Second, the number of study subjects was
relatively small and not sufficient large enough to lend
sufficient power to the results. Third, although all the
subjects were instructed to consume about 800 mg of
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uncertain how much calcium was actually consumed by
the subjects. Thus, double-blind randomized placebo-
controlled studies conducted on a sufficient number of
subjects under sufficient calcium supplementation are
needed to confirm the present results.
In conclusion, the present prospective head-to-head trial
showed that alendronate increased total hip BMD,
followed with reductions of the urinary level of NTX and
serum level of BSAP, while alfacalcidol sustained total
hip BMD and the urinary level of NTX and serum level of
BSAP. The study confirmed also the greater efficacy of
alendronate than alfacalcidol (active control) in increasing
hip BMD and reducing bone turnover in Japanese men
having osteoporosis or osteopenia with clinical risk
factors for fractures.
No pharmaceutical company had any involvement with
editorial/writing support. 
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